Diabetes decisions — 2025

The Veteran is granted a total disability rating based on individual unemployability (TDIU) due to his service-connected diabetes mellitus, type II, and its complications effective February 19, 2024, as well as special monthly compensation at the housebound rate for the same date.

The appeal for service connection for diabetes (DM) was dismissed as the Veteran withdrew the appeal in July 2025.

The Board denied service connection for hypertension, type II diabetes mellitus (DM II), and gastroesophageal reflux disease (GERD) as they are not related to the Veteran's service or a service-connected disability.

The Board remands the claims for further development, including obtaining additional medical opinions to address the etiology of the Veteran's diabetes mellitus type II and its relationship to in-service environmental exposures.

The Board remands the claims for service connection for type 2 diabetes mellitus, colon cancer, and an initial compensable rating for bilateral hearing loss to secure additional evidence.

The Board denied service connection for mantle cell lymphoma, emphysema, diabetes mellitus, Type II, bilateral foot neuropathy, and an acquired psychiatric disorder, including PTSD and antisocial personality disorder.

The Board granted service connection for a psychiatric disorder, other than posttraumatic stress disorder (PTSD), variously diagnosed as major depressive disorder, anxiety disorder, adjustment disorder, and panic disorder.

The Board denied the Veteran's claim for service connection for diabetes mellitus, type II, as there was no evidence of chronicity in service or manifestation to a compensable degree within the applicable presumptive period.

The Board denied service connection for traumatic brain injury and remanded claims for diabetes mellitus type II, Non-Hodgkin's lymphoma, and pancreatic cancer. Service connection was granted for left hip pain.

The Board denied service connection for a disability claimed as depleted uranium and remanded the claims for peripheral neuropathy, diabetes mellitus, an eye disorder, a prostate disorder, and a gastrointestinal disorder.

The Board granted service connection for coronary artery disease, Type II diabetes, and hypertension under the PACT Act. Peripheral arterial diseases were also granted as secondary to service-connected conditions.

The Board remands the issue of entitlement to service connection for the Veteran's cause of death, for purposes of entitlement to dependency and indemnity compensation (DIC), as further development is necessary.

The Board remands the claims for service connection for heart disability, diabetes mellitus, type II, and bilateral eye disabilities due to inadequate medical opinions regarding their relationship to toxic exposure during active duty.

The Veteran withdrew their appeal for all service connection and increased rating claims, including carpal tunnel syndrome, allergic rhinitis, bilateral hearing loss, left eye, left elbow, left hip, left shoulder, hemorrhoids, headaches, back, neck, hypertension, obstructive sleep apnea, and prediabetes.

The Board remands the claims for service connection for diabetes mellitus type II, right hip disability, left hip disability, and right knee disability to obtain new VA examinations as to the nature and etiology of the claimed disabilities.

The Board remands the claims for service connection for diabetes mellitus and hypertension to the AOJ for further development, as the AOJ failed to substantially comply with the Board's May 2025 remand instructions.

The Board remands the claims for further development, including directed research and VA examinations to address potential service connection based on chemical exposure.

The Board remands the claims for service connection for diabetes mellitus type II, congestive heart failure, and hypertension due to missing treatment records and an insufficient medical opinion.

The appeal for service connection for an anxiety disorder was dismissed, and the appeals for service connection for Parkinson's disease, a respiratory condition (COPD), a heart disability (coronary artery disease), rhinitis, diabetes mellitus, type II (diabetes), right lower extremity diabetic peripheral neuropathy, left lower extremity diabetic peripheral neuropathy, and right upper extremity diabetic peripheral neuropathy were remanded for further development.

The Board remands the claims for a rating in excess of 10 percent for diabetes mellitus, type II and an initial compensable rating for hypertension due to missing evidence.